Loading...
•
Dec 31, 2024
Conmed Q4 2024 Earnings Report
Conmed reported a 5.8% increase in sales and a 26.4% increase in adjusted diluted EPS for the fourth quarter of 2024.
Key Takeaways
CONMED Corporation announced solid sales and earnings growth for the fourth quarter and full-year 2024, with Q4 sales increasing 5.8% to $345.9 million and adjusted diluted EPS rising 26.4% to $1.34, despite persistent supply challenges.
Sales for Q4 2024 increased by 5.8% year-over-year to $345.9 million, or 6.0% in constant currency.
Diluted net earnings per share (GAAP) for Q4 2024 were $1.08, up from $1.05 in Q4 2023.
Adjusted diluted net earnings per share for Q4 2024 increased by 26.4% to $1.34.
Domestic revenue grew by 6.8% year-over-year, while international revenue increased by 4.4% (5.0% in constant currency).
Conmed
Conmed
Conmed Revenue by Segment
Conmed Revenue by Geographic Location
Revenue by Segment
Orthopedic Surgery Revenue
CapyFin.comGeneral Surgery Revenue
CapyFin.comSingle-Use Products Revenue
CapyFin.comCapital Products Revenue
CapyFin.comRevenue by Geographic Location
Domestic Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
CONMED expects full-year 2025 reported revenue to be between $1.344 billion and $1.372 billion, representing 4% to 6% constant currency growth, and adjusted diluted net earnings per share in the range of $4.25 to $4.40.
Positive Outlook
- Expected full-year 2025 revenue growth of approximately 4% to 6% in constant currency.
- Anticipated full-year 2025 adjusted diluted net earnings per share in the range of $4.25 to $4.40.
- Management is focused on improving operations and strengthening the foundation for future above-market revenue and profitability growth.
- The company aims for continued solid sales and earnings growth.
- The outlook suggests continued profitability.
Challenges Ahead
- Expected currency headwind of approximately 100 to 120 basis points on revenue growth.
- Anticipated currency headwind of approximately $0.15 to $0.20 on adjusted diluted net earnings per share.
- Guidance excludes any potential impact from recently announced tariffs, which could be a future negative.
- The company navigated persistent supply challenges in 2024, which may continue.
- The company is unable to provide a quantitative reconciliation for forward-looking adjusted diluted net earnings per share due to uncertainty and unreasonable effort regarding acquisition, integration, and other charges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income